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Quantitative real-time PCR for the measurement of
11beta-HSD1 and 11beta-HSD2 mRNA levels in tissues of
healthy dogs
Abstract
The 11beta-hydroxysteroid dehydrogenase (11beta-HSD) exists in two isoforms, 11beta-HSD1 and
11beta-HSD2. 11beta-HSD1 generates active cortisol from cortisone and appears to be involved in
insulin resistant states. 11beta-HSD2 protects the mineralocorticoid receptor from inappropriate
activation by glucocorticoids and is important to prevent sodium retention and hypertension. The
purposes of the present study were to develop two real-time PCR assays to assess 11beta-HSD1 and
11beta-HSD2 mRNA expression and to evaluate the tissue distribution of the two isoforms in dogs.
Thirteen different tissues of 10 healthy dogs were evaluated. Both real-time PCR assays were highly
specific, sensitive and reproducible. Highest 11beta-HSD1 mRNA expression was seen in liver, lung,
and renal medulla; highest 11beta-HSD2 mRNA expression in renal cortex, adrenal gland, and renal
medulla. Higher 11beta-HSD1 than 11beta-HSD2 mRNA levels were found in all tissues except adrenal
gland, colon, and rectum. Our results demonstrate that the basic tissue distribution of 11beta-HSD1 and
11beta-HSD2 in dogs corresponds to that in humans and rodents. In a next step 11beta-HSD1 and
11beta-HSD2 expression should be assessed in diseases like obesity, hypercortisolism, and hypertension
to improve our knowledge about 11beta-HSD activity, to evaluate the dog as a model for humans and to
potentially find new therapeutic options.
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 Quantitative Real-time PCR for the Measurement of 
11  -HSD1 and 11  -HSD2  mRNA Levels in Tissues of 
Healthy Dogs 
 Because of the role of these enzymes in a variety 
of physiological processes (e.g., gluconeogene-
sis, vasoconstriction, sodium balance, fetal devel-
opment, and reproduction) and pathological 
conditions (e.g. obesity, hypercortisolism, hyper-
tension), they have recently been the focus of 
intense investigations. Changes in 11  -HSD1 
expression and activity in certain tissues seem to 
be important in many common diseases such as, 
idiopathic obesity, diabetes mellitus, metabolic 
syndrome, and hypercortisolism (HC)  [7 – 12] . 
11  -HSD1 is therefore traded as a promising tar-
get for the therapy of humans with metabolic 
and endocrine disorders  [13,  14] . Abolishment of 
11  -HSD2 activity leads to overstimulation of the 
MR by cortisol, sodium retention, and hyperten-
sion. In humans, defects in the HSD11B2 gene are 
responsible for an inherited form of hyperten-
sion (apparent mineralocorticoid excess: AME) 
and milder forms of 11  -HSD2 dysfunctions are 
discussed in the pathogenesis of essential hyper-
tension  [2,  15] . Dysregulation of 11  -HSD2 is 
hypothesized as one cause of glucocorticoid 
resistance, a syndrome seen with prolonged glu-
 Introduction 
 & 
 Glucocorticoids play a major role in the metabo-
lism of almost all tissues of the body. They exist 
in an inactive (cortisone in humans and dogs, 11-
dehydrocorticosterone in rodents) and an active 
form (cortisol in humans and dogs, corticoste-
rone in rodents), whereby the prereceptor enzyme 
11  -hydroxysteroid dehydrogenase (11  -HSD) 
seems mainly responsible for their interconver-
sion  [1,  2] . Two isoforms of 11  -HSD have been 
identiﬁ ed, 11  -HSD1 and 11  -HSD2. The 11  -
HSD1 is NADP(H) dependent and acts predomi-
nately as an oxoreductase  in vivo , generating 
active cortisol from cortisone  [3] . It potentates 
the actions of glucocorticoids in tissues and is 
widely distributed in the body with highest 
expression in liver and adipose tissue  [4] . The 
11  -HSD2 utilizes NAD to inactivate cortisol to 
cortisone. It serves to protect the mineralocorti-
coid receptor (MR) from excess cortisol and is 
expressed in MR-rich tissues, such as kidney, 
colon, and salivary glands  [5,  6] . 
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 Abstract 
 & 
 The 11  -hydroxysteroid dehydrogenase (11  -
HSD) exists in two isoforms, 11  -HSD1 and 11  -
HSD2. 11  -HSD1 generates active cortisol from 
cortisone and appears to be involved in insulin 
resistant states. 11  -HSD2 protects the miner-
alocorticoid receptor from inappropriate acti-
vation by glucocorticoids and is important to 
prevent sodium retention and hypertension. The 
purposes of the present study were to develop 
two real-time PCR assays to assess 11  -HSD1 
and 11  -HSD2  mRNA expression and to evalu-
ate the tissue distribution of the two isoforms 
in dogs. Thirteen different tissues of 10 healthy 
dogs were evaluated. Both real-time PCR assays 
were highly speciﬁ c, sensitive and reproducible. 
Highest 11  -HSD1  mRNA expression was seen 
in liver, lung, and renal medulla; highest 11  -
HSD2  mRNA expression in renal cortex, adrenal 
gland, and renal medulla. Higher 11  -HSD1 than 
11  -HSD2  mRNA levels were found in all tissues 
except adrenal gland, colon, and rectum. Our 
results demonstrate that the basic tissue distri-
bution of 11  -HSD1 and 11  -HSD2 in dogs corre-
sponds to that in humans and rodents. In a next 
step 11  -HSD1 and 11  -HSD2 expression should 
be assessed in diseases like obesity, hypercorti-
solism, and hypertension to improve our knowl-
edge about 11  -HSD activity, to evaluate the dog 
as a model for humans and to potentially ﬁ nd 
new therapeutic options. 
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cocorticoid treatment in humans  [16] . As for 11  -HSD1, modula-
tion of 11  -HSD2 activity may offer a future therapeutic approach 
in these conditions. 
 Like in humans and rodents, two 11  -HSD isoenzymes have 
been described in dogs, but substantiated knowledge about 
their tissue distribution and their function in physiological and 
pathological conditions has so far been lacking  [17,  18] . A reliable 
method to assess 11-  HSD1 and 11-  HSD2 levels would help to 
gain information on enzyme activity in speciﬁ c diseases and to 
assess the dog as a model for human medicine. Enzyme proﬁ les 
can be analyzed by measuring the protein itself or the amount of 
messenger ribonucleic acid (mRNA) in a tissue as an indicator of 
gene transcription. Close correlation between 11  -HSD mRNA 
expression and 11  -HSD activity has been shown in humans and 
rodents  [9,  19] . Measuring 11  -HSD mRNA in tissues is therefore 
considered a reliable tool to assess 11  -HSD activity. 
 The purposes of the study reported here were to design two 
quantitative real-time PCR assays to evaluate mRNA levels of 11-
  HSD1 and 11-  HSD2 in dogs and to asses the 11-  HSD expres-
sion and tissue distribution of the two isoforms in healthy dogs. 
 Material and Methods 
 & 
 Animals 
 Tissues of 5 intact male and 5 intact female (4 in metestrus, 1 in 
estrus) Beagle dogs (Marshall Europe, Green Hill, Montichiari, 
Italy), with a median age of 12. 5 months (range, 11 – 14 months) 
and a median body weight of 8.9  kg (range, 7.3 – 10.5  kg) were 
used. Dogs were maintained at Novartis Pharma Schweiz AG, 
Safety Proﬁ ling  & Assessment, Muttenz, Switzerland using 
standard colony conditions. They were kept in groups of 2 – 5 at 
the Toxicology unit of Novartis Pharma Schweiz AG, provided 
unlimited access to water, and fed a certiﬁ ed dog diet (Provimi 
Kliba AG, Kaiseraugst, Switzerland, No. 3353). Prior to being 
euthanized, they had participated as control dogs in a toxico-
logical research experiment and had received deionized water 
(14  ml / kg orally) daily as a placebo for 4 weeks. Animal studies 
were approved by the Swiss regional Veterinary Service and 
conducted in accordance with guidelines established by the Ani-
mal Welfare Act of Switzerland. 
 Sample collection 
 Samples were collected within 30 minutes of euthanasia of 13 
tissues (renal cortex, renal medulla, liver, spleen, visceral adi-
pose tissue, adrenal gland, pancreas, jejunum, colon, rectum, 
cardiac ventricle, lung, and aortic wall) and directly frozen in liq-
uid nitrogen. The tissues were then stored at   −  80  °  C. 
 RNA isolation and cDNA synthesis 
 About 30  mg of tissue was cut out from the frozen samples and 
placed in a 2  ml Eppendorf tube containing 600   l of RLT buffer 
(Qiagen, Hombrechtikon, Switzerland) and two 3  mm steel 
beads (Schieritz  & Hauenstein AG, Arlesheim, Switzerland). The 
samples were homogenized and lysed by mixing for 2 – 3 min-
utes at 30  Hz in a Mixer Mill device (Qiagen). After mixing, the 
samples were incubated for 15 minutes on ice to reduce the 
foam that had formed during the homogenization step. Total 
RNA was extracted with the RNeasy Mini kit (Qiagen) according 
to the manufacturer ’ s protocol. RNA was eluted with 40   l of 
RNase-free water and stored at   −  80  °  C until reverse-transcrip-
tion. Negative controls containing only phosphate buffered 
saline (PBS 1  ×  ) were also co-extracted to monitor eventual 
cross-contamination during the RNA isolation step. 
 Genomic DNA was digested and RNA reverse-transcribed by the 
QuantiTect Reverse Transcription Kit (Qiagen) according to the 
manufacturer ’ s protocol. The cDNA was diluted to 50   l total vol-
ume with RNase-free water and stored at   −  20  °  C. 
 TaqMan primers and probes 
 Probe and primer sequences were designed using PrimerEx-
press ™ software (Version 2.0. , Applied Biosystems, Rotkreuz, 
Switzerland) based on the canine 11  -HSD1 (AY728264.1), 11  -
HSD2 (AY832857.1), and GAPDH (AB038240) sequences depos-
ited in the GenBank. 
 The primer and probe sets were designed such as the amplicons 
size was 50 – 150  bp, the primer size 9 – 40  bp, the primer melting 
temperature (T m ) 58 – 60  °  C with a maximum difference of 2.0  °  C, 
and the probe T m 68 – 70  °  C. The probe and primer sequences 
were selected on the basis of following criteria: (1) the sense 
and antisense primers were placed in two consecutive exons of 
the gene and the probe spanned the junction of two exons where 
possible, (2) lack of predicted dimer formation with correspond-
ing primers, (3) lack of self-annealing, (4) no G at 5  -end of the 
probe, and (5) probe melting temperature 10  °  C higher than 
primer melting temperature. All probes were labeled at the 5  -
end with the ﬂ uorescent reporter dye FAM (6-carboxyﬂ uores-
cein) and at the 3  -end with the ﬂ uorescent quencher dye 
TAMRA [5, (6)carboxytetramethylrhodamine]. The primer and 
probe sequences are listed in  Table 1 . 
 Speciﬁ city of PCR primers 
 In order to establish that the primers speciﬁ cally ampliﬁ ed the 
sequences selected, the PCR products were separated by gel 
electrophoretic analysis in a 3  % agarose gel (Invitrogen, Paisley, 
Scotland, UK). The PCR products of 11  -HSD1 and 11  -HSD2 
were cut out from the gel and puriﬁ ed using the MiniElute Gel 
Extraction Kit (Qiagen) according to the manufacture ’ s protocol. 
Sequencing was performed from both sides. Brieﬂ y, cycle 
sequencing was performed with approximately 3  ng of DNA and 
3.3  pmol of product-speciﬁ c primers using the BidDye Termina-
tor Cycle Sequencing Ready Reaction Kit v1.1 (Applied Biosys-
tems). Cycling conditions were as follows: 1 minute at 96  °  C, 
then 25 cycles at 96  °  C for 30 seconds and 50  °  C for 15 seconds, 
 Table 1  Primer and probe sequences for canine 11  -HSD 1, 11  -HSD 2, 
GAPDH 
 Primer name  Sequence (5  – 3  )  Length 
(bp) 
 forward primer HSD1.613f 
 reverse primer HSD1.689r 
 probe HSD1.39p 
 AAGGTCAATGTGTCGAT-
CACTCTCT 
 ATCCCAGAAACGGCCTTCAT 
 TATCCTCGGCCTCAT-
AAACACAGACACAGC a 
 25 
 20 
 30 
 forward primer HSD2.468f 
 reverse primer HSD2.538r 
 probe HSD2.489p 
 GGGTCAAGGTCAGCGTCATC 
 CTCCCAATGTCCCACATTCC 
 AGCCTGGCTGCTTTAAGACA-
GAGTCCG a 
 20 
 20 
 27 
 forward primer GAPDH 
 reverse primer GAPDH 
 probe GAPDH 
 GATGGGCGTGAACCATGAG  
 TCATGAGGCCCTCCACGAT 
 CCCTCAAGATTGTCAGCAAT-
GCCTCCT a 
 19 
 19 
 27 
 a 5  -end labeled with the reporter dye FAM; 3  -end labeled with quencher dye TAMRA 
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followed by 60  °  C for 4 minutes. Products were puriﬁ ed using 
the DyeEx Spin column (Qiagen), and analyzed on the ABI 
Prism ™ 310 Genetic Analyzer (Applied Biosystems). The 
sequences obtained were aligned to one consensus sequence by 
SeqScape (Version 1.1, Applied Biosystems) and then compared 
to reference sequences deposited in the GenBank. 
 TaqMan  ®  ﬂ uorogenic real-time PCR assay 
 DNA was ampliﬁ ed and quantiﬁ ed in an ABI Prism 7700 sequence 
detection system (Applied Biosystems). The three PCR ’ s were 
performed in separate tubes. PCR reactions were prepared with 
12.5   l of qPCR ™ Mastermix (Eurogentec, Seraing, Belgium), a 
ﬁ nal concentration of 900  nM primers (Microsynth, Balgach, 
Switzerland), 250  nM of ﬂ uorogenic probe (Microsynth and 
Eurogentec) and 5   l of template in a 25   l total reaction volume. 
After an initial step of 2 minutes at 50  °  C required for optimal 
AmpErase  ®  UNG activity, a denaturation of 10 minutes at 95  °  C 
was followed by 45 cycles of 95  °  C for 15 seconds and 60  °  C for 1 
minute. 
 Ampliﬁ cation efﬁ ciency of the real-time PCR assay 
 The ampliﬁ cation efﬁ ciencies of all three assays were deter-
mined in duplicates using serial 10-fold dilutions of cDNA. The 
efﬁ ciencies of these dilutions were compared to each other by 
assessing the slopes (s) of the curves (threshold cycle versus 
dilution) obtained by PCR ampliﬁ cation of serial dilutions of the 
same template. The efﬁ ciencies of the assays for different targets 
were considered equal if the difference of the slope (  s) was 
smaller than 0.1. Ampliﬁ cation efﬁ ciencies were calculated as 
10 1 /  −  s – 1  [20] . 
 Precision of the quantitative real-time PCR assay 
 Within- and between-run precision of the quantitative real-time 
PCR assays were assessed by multiple measurements of several 
dilutions of the cDNA. Three cDNA samples were evaluated in 10 
replicates (within-run precision) and in ﬁ ve separate experi-
ments (between-run precision). For all measurements, mean 
value, standard deviation, and coefﬁ cients of variation (CV) were 
calculated for the threshold cycle (CT) values (CV CT ). 
 Relative quantitation of mRNA expression by real-time 
PCR 
 The expression of 11  -HSD1 and 11  -HSD2  cDNA templates was 
quantiﬁ ed by means of real-time PCR. In order to minimize vari-
ations all sequences of interest were ampliﬁ ed in parallel from 
one aliquot of cDNA on the same plate. Relative quantiﬁ cation of 
the template was achieved using the comparative C T method 
and is reported as relative transcription or the  n -fold differences, 
relative to the calibrator cDNA. For each sample, C T differences 
between the target and the internal control (GAPDH) were cal-
culated (  C T ) and served to normalize for differences in the 
quantity of total nucleic acid added to each reaction and for the 
efﬁ ciency of the RT step. The C T of the calibrator was subtracted 
from the   C T of each sample to give the value    C T . The amount 
of target was calculated by 2-   CT, resulting in evaluation of the 
sample as a  n -fold difference relative to the calibrator. For each 
animal evaluated the C T value of the renal sample was chosen as 
a calibrator. 
 Statistical analysis 
 Due to methological reasons (selection of renal cortex as calibra-
tor) a statistical comparison of 11  -HSD mRNA level of renal cor-
tex to that of other tissues was not possible. The statistical 
analyses were therefore performed without values of renal cor-
tex. Results were analyzed by use of nonparametric statistical 
methods (SPSS 11.0 for Windows, SPSS Inc, Chicago, Ill, USA and 
GraphPad Prism 4, San Diego, California, USA). Differences 
between or within organs were tested by the use of Friedman ’ s 
repeated measures test. If a signiﬁ cant difference was detected 
pairwise comparison was performed using the Wilcoxon 
matched paired test. Differences between sexes were tested by 
use of Kruskal – Wallis H test and pairwise comparison was per-
formed by Mann – Whitney U test. Differences were considered 
signiﬁ cant at values of p  ≤  0.05. 
 Results 
 & 
 Speciﬁ city of TaqMan primer combinations 
 The targets were ampliﬁ ed using the respective primer set with-
out probe. When the PCR products were analyzed by gel electro-
phoretic analysis, the 11  -HSD1, the 11  -HSD2, and the GAPDH 
systems, all produced a single band at the expected length 
(    Fig. 1 ). Sequencing of the 11  -HSD1 and the 11  -HSD2 prod-
ucts revealed identical nucleotide sequences compared to those 
for dogs available in the public sequence database (data not 
shown). 
 Ampliﬁ cation efﬁ ciencies of the PCR assays 
 Ampliﬁ cation efﬁ ciencies of the real-time assays were deter-
mined analyzing 10-fold serial dilutions of cDNA of each tran-
script. The slopes of the dilution versus threshold cycle curves 
were   −  3.30,   −  3.40,   −  3.33 for 11  -HSD1, 11  -HSD2 and GAPDH, 
←100 bp
←200 bp
←500 bp
M 1 2 3 4 5 6 M 
11β-HSD1
11β-HSD2
GAPDH
← 1000 bp
 Fig. 1  Speciﬁ city of TaqMan primer combinations. Gel electrophoretic 
analysis of the PCR products in a 3  % agarose gel. Lanes: M: 100 base pair 
(bp) ladder DNA molecular weight marker (SmartLadder SF, Eurogentec, 
Seraing, Belgium); 1: cDNA sample liver; 2: negative control; 3: cDNA 
sample rectum; 4: negative control; 5: cDNA sample cardiac ventricle; 6: 
negative control. The expected PCR product lengths are: 11  -HSD1: 77  bp; 
11  -HSD2: 71  bp; GAPDH: 131  bp. 
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respectively (    Fig. 2 ). These values were calculated into ampli-
ﬁ cation efﬁ ciencies of 100  % , 97  % , and 99  % for the 11  -HSD1, the 
11  -HSD2, and the GAPDH DNA PCR, respectively. 
 Precision of the quantitative real-time PCR assays 
 To assess within- and between-run precision, dilutions of cDNA 
were assayed in replicates on the same plate or in multiple 
experiments. The CV CT of the within-run precision experiments 
were 0.9 – 1.9  % , 0.3 – 0.8  % , and 0.7 – 1.2  % for 11  -HSD1, 11  -HSD2, 
and GAPDH, respectively. The CV CT of the between-run experi-
ments were 0.2 – 1.0  % , 1.6 – 1.8  % , and 1.1 – 1.4  % , respectively. 
 Determination of mRNA load of different tissues in dogs 
 11  -HSD1  mRNA 
 11  -HSD1  mRNA could be detected in every tissue (    Fig. 3 ). 
Comparing all tissues, the highest 11  -HSD1  mRNA levels were 
revealed in liver and the lowest in cardiac ventricle. Other tis-
sues with high 11  -HSD1  mRNA levels were lung, renal medulla, 
and pancreas. 11  -HSD1  mRNA levels of spleen, adipose tissue, 
adrenal gland, jejunum, colon, rectum, and aortic wall were sig-
niﬁ cantly lower than those of liver, lung and renal medulla and 
signiﬁ cantly higher than those of cardiac ventricle. 
2 3 4 5 6 7
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11beta-HSD1
11beta-HSD2
cGAPDH
Log Serial 10-fold Dilution
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 Fig. 2  Ampliﬁ cation efﬁ ciency of the 11  -HSD1, the 11  -HSD2 and the 
GAPDH real-time PCR assays. To assess the ampliﬁ cation efﬁ ciency of the 
assays, 10-fold serial dilutions of cDNA were analyzed. The assays were run 
in duplicates and means are depicted. The slopes of the curves (logarithmic 
dilution vs. threshold cycle) for 11  -HSD1, 11  -HSD2 and GAPDH, did not 
differ more than 0.1. 
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 Fig. 3  11  -HSD1 and 11  -HSD2  mRNA expres-
sion in different tissues of healthy dogs. Relative 
11  -HSD1 and 11  -HSD2  mRNA load normalized 
to GAPDH in different tissues of 10 healthy dogs. 
Adrenal gland was only evaluated in 9 dogs. The C T 
value of the renal cortex sample was chosen as a 
calibrator. 
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 11  -HSD2  mRNA 
 11  -HSD2  mRNA could be detected in every tissue (    Fig. 3 ). 
Comparing all tissues, the highest 11  -HSD2  mRNA levels were 
revealed in adrenal gland and the lowest in cardiac ventricle 
and liver. Other tissues with high 11  -HSD2  mRNA levels were 
renal medulla, colon, and rectum. 11  -HSD1  mRNA levels of 
spleen, adipose tissue, pancreas, jejunum, lung, and aortic wall 
were signiﬁ cantly lower than those of adrenal gland, colon, and 
rectum, but signiﬁ cantly higher than those of cardiac ventricle 
and liver. 
 Comparison of 11  -HSD1 and 11  -HSD2  mRNA levels of 
different tissues 
 Messenger RNA levels of 11  -HSD1 were signiﬁ cantly higher 
than those of 11  -HSD2 in renal medulla, liver, spleen, adipose 
tissue, pancreas, cardiac ventricle, lung, and aortic wall. Con-
versely, mRNA levels of 11  -HSD2 were higher than those of 
11  -HSD1 in adrenal gland, colon, and rectum, although not sig-
niﬁ cantly. No correlation was found between the mRNA levels of 
11  -HSD1 and 11  -HSD2 in tissues. 
 Comparison of 11  -HSD1 and 11  -HSD2  mRNA values 
between sexes 
 Female dogs had signiﬁ cantly higher 11  -HSD1  mRNA levels in 
adipose tissue than male dogs. For all other tissues 11  -
HSD1  mRNA values were not signiﬁ cantly different between 
sexes ( Table 2 ). 11  -HSD2  mRNA levels did not differ between 
female and male dogs ( Table 3 ). 
 Discussion 
 & 
 There have been a number of studies using real-time PCR or 
real-time RT-PCR to examine 11  -HSD expression in several spe-
cies, including human, rat, and pig  [9,  21 – 23] . To our knowledge, 
however, our study represents the ﬁ rst report of the develop-
ment of a real-time PCR assay for 11  -HSD1 and 11  -HSD2 in 
dogs. The two real-time PCR assays described were highly sensi-
tive for the quantiﬁ cation of 11  -HSD1 and 11  -HSD2  mRNA 
expression. The newly designed primers were able to speciﬁ -
cally amplify the target, since sequencing of the ampliﬁ ed frag-
ments revealed identical nucleotide sequences compared to 
those for dogs available in the public sequence database. The 
ampliﬁ cation efﬁ ciencies of our three PCR systems were less 
than 10  % different, therefore allowing relative quantiﬁ cation of 
enzyme transcripts. 
 The developed real-time PCR systems were used to assess 11  -
HSD1 and 11  -HSD2 expression and tissue distribution in dogs. 
Our results reveal that in dogs 11  -HSD1 is widely distributed in 
the body, with especially high expression in the liver whereas 
 Table 2  11  -HSD1  mRNA levels in different tissues of healthy male and female dogs 
  Male dogs  Female dogs 
  Median  Range  Median  Range 
 renal cortex  1.0  –  1.0  – 
 renal medulla  0.9  0.15 – 3.7  5.2  0.9 – 21.4 
 liver  7.3  2.2 – 10.8  82.7  5.9 – 224.4 
 spleen  0.3  0.09 – 0.42  0.5  0.17 – 1.8 
 adipose tissue  0.06  0.02 – 0.27  1.1 *  0.24 – 1.9 
 adrenal gland  0.13  0.06 – 0.33  0.54  0.07 – 1.4 
 pancreas  0.15  0.1 – 10.6  3.2  0.13 – 10.2 
 jejunum  0.02  0.005 – 0.14  0.36  0.02 – 3.4 
 colon  0.01  0.008 – 0.11  0.08  0.02 – 0.59 
 rectum  0.03  0.006 – 1.1  0.1  0.04 – 1.3 
 cardiac ventricle  0.005  0.001 – 0.024  0.04  0.001 – 0.08 
 lung  1.13  0.35 – 7.0  16.4  1.5 – 24.4 
 aortic wall  0.02  0.002 – 1.0  0.28  0.07 – 0.9 
 * Signiﬁ cantly different compared to male dogs. 
 Table 3  11  -HSD2  mRNA levels in different tissues of healthy male and female dogs 
  Male dogs  Female dogs 
  Median  Range  Median  Range 
 renal cortex  1  –  1  – 
 renal medulla  0.64  0.3 – 2  0.5  0.2 – 0.9 
 liver  0.0004  0.0003 – 0.002  0.0002  0.0002 – 0.0007 
 spleen  0.008  0.003 – 0.02  0.004  0.002 – 0.005 
 adipose tissue  0.005  0.002 – 0.019  0.002  0.002 – 0.01 
 adrenal gland  1  0.67 – 4.1  0.765  0.3 – 1.2 
 pancreas  0.006  0.002 – 0.01  0.004  0.002 – 0.008 
 jejunum  0.03  0.003 – 0.16  0.02  0.009 – 0.05 
 colon  0.6  0.006 – 1.3  0.2  0.3 – 0.13 
 rectum  0.3  0.1 – 0.86  0.3  0.07 – 0.69 
 cardiac ventricle  0.0002  0.0001 – 0.006  0.00008  0.00004 – 0.0002 
 lung  0.04  0.009 – 0.11  0.02  0.008 – 0.03 
 aortic wall  0.006  0.0006 – 0.01  0.002  0.001 – 0.006 
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11  -HSD2 is predominant in MR-rich tissues, such as kidney, 
colon and rectum. This is in agreement with results from humans 
and rodents and could be indicative for the same physiological 
and pathophysiological role of these enzymes in these species. 
For some tissues, however, differences in 11  -HSD1 and 11  -
HSD2 expression between dogs, rodents, and humans exist. 
First, in dogs and rodents a moderate level of 11  -HSD1 is found 
in kidneys, while in humans little if any could be detected 
 [24,  25] . Second, adrenal glands of dogs and rats express both 
isoforms  [26] . By contrast, human adrenals express 11  -HSD1 
but not 11  -HSD2  [2] . Third, low 11  -HSD levels are found in the 
cardiac ventricle of dogs, 11  -HSD1 being signiﬁ cantly higher 
than 11  -HSD2. The low levels are in agreement with results 
from humans, although the human heart mainly contains 11  -
HSD2  [27,  28] . Finally, several tissue-speciﬁ c sex differences in 
11  -HSD expression and activity have been demonstrated in 
humans and rodents  [29,  30] . In dogs, differences were only 
detected in adipose tissue: females having higher 11  -HSD1 
concentrations than males. 
 There are some drawbacks in our study. First, conﬁ rmation of 
the mRNA expression results on protein level by western blot 
analysis or by measuring the enzyme activity would have 
strengthened our data. However, because close correlation 
between 11  -HSD mRNA and 11  -HSD activity has been shown 
in humans and rodents, mRNA levels seemed reliable to study 
the basic tissue distribution of the two isoforms  [9,  19] . Second, 
one cannot exclude that the treatment with deionized water for 
4 weeks somehow inﬂ uenced the 11  -HSD expression in the tis-
sues. This, however, seems unlikely, because the daily amount of 
water applied to the dogs was far below than the daily need of 
water. 
 Our results demonstrate that the basic tissue distribution of 11  -
HSD1 and 11  -HSD2 in dogs corresponds to that in humans and 
rodents; 11  -HSD1 being abundant in the whole body and 11  -
HSD2 being especially high in MR-rich tissues. Whether the 
physiological and pathophysiological functions of the two iso-
forms coincide in dogs and humans has now to be established. 
Therefore, 11  -HSD1 and 11  -HSD2 expression and activity have 
to be studied in diseases expected to be inﬂ uenced by altered 
11  -HSD activity, such as obesity, insulin resistance, diabetes 
mellitus, hypercortisolism, hypertension, and cardiovascular 
problems. Knowledge about 11  -HSD1 and 11  -HSD2 expres-
sion in these conditions could help to further understand the 
diseases or to ﬁ nd new and helpful therapeutic options. If it 
emerges that in diseased dogs 11  -HSD1 and 11  -HSD2 activity 
are altered in the same way as in humans, dogs could act as a 
model for human medicine. This would especially be interest-
ing, because dogs suffer from many diseases of large human 
importance (obesity, hypertension, HC). 
 In summary, we have presented an easy and reproducible 
method to evaluate the mRNA levels of 11  -HSD1 and 11  -HSD2 
in different tissues of dogs. In dogs, 11  -HSD1  mRNA levels were 
highest in liver, lung, renal medulla, and pancreas; and 11  -
HSD2  mRNA levels were highest in renal cortex, adrenal gland, 
renal medulla, colon, and rectum. 
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